Efficacy of Presurgical Short‐Term Endocrine Therapy During the Waiting Period for Surgery in Postmenopausal Hormone Receptor‐Positive Breast Cancer
The Breast Journal · 2025
DOI: 10.1155/tbj/9976413 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Breast Journal, 2025. Verfasst von Yuka Maeda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, School of Medicine, Teikyo University, Tokyo, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Aromatase Inhibitors, Antineoplastic Agents, Hormonal. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Although presurgical endocrine therapy has been used to enhance the rate of breast cancer conservation, its prognostic relevance is unknown. The search for a valid prognostic factor equivalent to pathological complete response in presurgical chemotherapy remains a challenge in presurgical endocrine therapy. This study investigated the efficacy of presurgical short‐term endocrine therapy (preSTE) and assessed prognostic factors, including the preoperative endocrine prognostic index (PEPI) score.
Methods
From October 2012 to November 2021, 269 postmenopausal women diagnosed with hormone receptor‐positive (HR+), human epidermal growth factor receptor 2 negative breast cancer underwent endocrine therapy with a nonsteroidal aromatase inhibitor during the presurgical waiting period. The primary endpoint was to assess the changes in tumor size using ultrasonography, and Ki67 expression levels before and after preSTE. The secondary endpoint was the prognosis of patients categorized using the PEPI score.
Results
The median age of patients was 68 years (range, 41–89 years). The median tumor size was 1.65 cm (range, 0.4–7.5 cm). The average pretreatment Ki67 expression level was 10% (range, 0%–90%). The median duration of endocrine therapy was 39 days (range, 2–88 days). Tumor diameter and Ki67 expression levels were significantly decreased to 1.43 cm (range, 0.45–5.83 cm) and 3.0% (range, 0%–85%) after preSTE, respectively. After the median observation period of 928 days, patients with PEPI scores ≥ 4 showed worse disease‐free survival compared with those with lower PEPI scores. In terms of mortality, patients with PEPI score ≥ 4 had worse overall survival than did patients with lower PEPI scores.
Conclusions
Endocrine therapy during the waiting period for surgery might be effective in reducing tumor size, and the Ki67 expression level and PEPI score might be useful in predicting the prognosis of patients with postmenopausal HR+ breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, School of Medicine, Teikyo University, Tokyo, Japan.
ORCID-Profile: Yuka Maeda, Ayana Sato, Akiko Matsumoto, Tatsuhiko Ikeda, Hiromitsu Jinno
Zitieren
APA
Maeda, Y., Sato, A., Matsumoto, A., Ikeda, T., & Jinno, H. (2025). Efficacy of Presurgical Short‐Term Endocrine Therapy During the Waiting Period for Surgery in Postmenopausal Hormone Receptor‐Positive Breast Cancer. The Breast Journal. https://doi.org/10.1155/tbj/9976413
Vancouver
Maeda Y, Sato A, Matsumoto A, Ikeda T, Jinno H. Efficacy of Presurgical Short‐Term Endocrine Therapy During the Waiting Period for Surgery in Postmenopausal Hormone Receptor‐Positive Breast Cancer. The Breast Journal. 2025. doi:10.1155/tbj/9976413
BibTeX
@article{Maeda2025,
author = {Maeda, Yuka and Sato, Ayana and Matsumoto, Akiko and Ikeda, Tatsuhiko and Jinno, Hiromitsu},
title = {Efficacy of Presurgical Short‐Term Endocrine Therapy During the Waiting Period for Surgery in Postmenopausal Hormone Receptor‐Positive Breast Cancer},
journal = {The Breast Journal},
year = {2025},
doi = {10.1155/tbj/9976413}
}
EUVIMED